奧鋭特(605116.SH):擬發行不超8.12億元可轉債、用於308噸特色原料藥及2億片抗腫瘤製劑項目(一期)等等
格隆匯4月3日丨奧鋭特(605116.SH)公佈,公司擬發行可轉債總額不超過人民幣81212萬元(含81212萬元),扣除發行費用後,37512萬元用於308噸特色原料藥及2億片抗腫瘤製劑項目(一期),23414萬元用於年產300KG司美格魯肽和20噸帕羅韋德原料藥生產線及配套設施建設項目(一期),3286萬元用於年產3億雌二醇/雌二醇地屈孕酮複合包裝片和3億多替拉韋鈉片生產線建設項目(一期),1.7億元用於補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.